Skip to main content

Table 1 Patient characteristics

From: Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT

Characteristics

All

Radical RT group

Salvage RT group

Oligomts RT group

Patient groups

    

Patients (n)

43

21

17

5

Age (years), (range)

70 (58–84)

72 (65–81)

69 (58–84)

68 (65–71)

Gleason score

    

6–7

24

14

8

2

8–9

18

7

8

3

TNM stage

    

Tx

3

2

1

3

T1-2

25

9

11

2

T3-4

18

10

5

2

N0/x

38

20

16

3

N1-2

5

1

1

3

M0/x

41

21

17

2

M1

2

 

Initial PSA (ng/ml) median (range)

28.4 (6.3–530)

52.3 (11–530)

10.4 (6.3–21)

22.6 (6.9–52)

PSA pre PSMA-PET/CT (ng/ml) median (range)

4.34 (0.1–30.6)

9.4 (0.2–30.6)

2.8 (0.1–21.8)

0.8 (0.1–1.9)

ADT at time of PET

27

21

1

5

PSMA-PET/CT revealed metastases (LN, Bones, FR)

30

11

15

4

Lymph nodes

10

4

7

1

Bones

6

3

1

2

Lymph nodes and bones

5

4

1

FR (FR + nodes)

6 (1)

6 (1)

  1. PSA, prostate-specific antigen; PSMA, PET/CT prostate-specific membrane antigen positron emission tomography/computed tomography; ADT, androgen deprivation therapy; LNs, lymph nodes; FR,fossa recurrence; RT, radiation therapy; Oligomts, oligometastatic; Salvage RT, post-prostatectomy RT